EuroPCR 2022 | GLOBAL SYMPLICITY Registry

The GLOBAL SYMPLICITY Registry is the largest study, with the longest followup, of real-world patients (real world data) presenting high blood pressure, treated with renal denervation. 

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

Time in Target Range (TTR), estimates the time a patient needs to control their blood pressure, and is an independent predictor of cardiovascular events. 

The aim of this registry, open, multicenter, and observational, was to assess the impact of improved TTR after radiofrequency renal denervation on cardiovascular outcomes, and estimate cardiovascular reduction associated to improved blood pressure control. 

3077 consecutive uncontrolled hypertensive patients, treated with the Symplicity™ (Flex o Spyral) radiofrequency renal denervation system, were included and followed up to 3 years. Cutoff values for TTR were office <140 mmHg and 24-hour ambulatory blood pressures <130 mmHg.

Mean age was 60±12 years, office BP was 166 mmHg ±25 and ambulatory BP was 154±19 mmHg; patients were treated with 4.9±1.7 antihypertensive medication classes. Office blood pressure saw a reduction vs. baseline of -13.2 at 6 months, -14 at one year, -15.3 at two years and -16.7 at 3 years (P<0.001). This progressive benefit was also seen in the ambulatory branch, with reduced hypertension values regardless the number of antihypertensives (p=0.007).

Read also: EuroPCR 2022 | ASTRO TAVR: Should we treat post TAVR Strokes with Neurointervention?

TTR significantly and progressively increased at followup: 28.2% at 3 months vs. 34.9% at 3 years. As regards safety outcomes, there was a small number of events: creatinine elevation >50% in 1.3%, chronic kidney disease, advance stage, in 1.9% and the presence of new renal stenosis (>70%) in 0.3% of cases.

When looking at MACE, patients with TTR >50% presented fewer events compared against TTR 0-50% (2.9% vs 6.2%; P<0.0001). 10% TTR increase was associated to 16% MACE reduction. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Source: Presented by Mahfoud, F. en EuroPCR 2022, París, Francia.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...